Mersana Therapeutics, Inc. (MRSN)
NASDAQ: MRSN · Real-Time Price · USD
0.3189
-0.0161 (-4.81%)
At close: May 9, 2025, 4:00 PM
0.3340
+0.0151 (4.74%)
After-hours: May 9, 2025, 7:44 PM EDT
Mersana Therapeutics Revenue
In the year 2024, Mersana Therapeutics had annual revenue of $40.50M with 9.88% growth. Mersana Therapeutics had revenue of $16.36M in the quarter ending December 31, 2024, with 52.89% growth.
Revenue (ttm)
$40.50M
Revenue Growth
+9.88%
P/S Ratio
0.96
Revenue / Employee
$397,029
Employees
102
Market Cap
39.74M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 40.50M | 3.64M | 9.88% |
Dec 31, 2023 | 36.86M | 10.27M | 38.65% |
Dec 31, 2022 | 26.58M | 26.54M | 61,716.28% |
Dec 31, 2021 | 43.00K | -785.00K | -94.81% |
Dec 31, 2020 | 828.00K | -41.30M | -98.03% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
MRSN News
- 5 days ago - Mersana Therapeutics Announces Strategic Restructuring and Reprioritization Plan Focused on Advancing Emi-Le in Triple-Negative Breast Cancer - GlobeNewsWire
- 18 days ago - Mersana Therapeutics Announces Upcoming Emi-Le Oral and Poster Presentations at ASCO 2025 Annual Meeting - GlobeNewsWire
- 5 weeks ago - Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 weeks ago - Mersana Therapeutics Announces Upcoming Oral Presentation of Emi-Le Clinical Data at European Society for Medical Oncology (ESMO) Breast Cancer 2025 Annual Congress - GlobeNewsWire
- 2 months ago - Mersana Therapeutics, Inc. (MRSN) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 2 months ago - Mersana Therapeutics to Present at Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Mersana Therapeutics to Host Fourth Quarter and Year End 2024 Conference Call on March 3, 2025 - GlobeNewsWire